Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Proteomic analysis by SELDI-TOF on the tumor biopsy and blood samples Histological response according To Chevallier and Sataloff
6 months
No
BONNETERRE Jacques, MD, PhD
Principal Investigator
Centre Oscar Lambret
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
SPAM 2006-10
NCT00911911
January 2007
July 2009
Name | Location |
---|